Talip Uçar | Inside Boltz's open-source bet on the future of AI-driven drug discovery

Talip Uçar | Inside Boltz's open-source bet on the future of AI-driven drug discovery

When an AI model generates an image, you can tell at a glance whether it's any good. In life sciences, that feedback loop is fragmented across data, modelling, experiments, and the clinic, and signal gets lost at every handoff. In this episode, we sit down with Talip Uçar, founding member of Boltz, to discuss why data is the real competitive advantage, why pharma needs a tech-first mindset to make AI work, and why a unified data fabric remains the field's missing layer. Watch the full conversation and read the transcript → https://enpicom.com/models-molecules/talip-ucar-inside-boltzs-open-source-bet-on-the-future-of-ai-driven-drug-discovery/ [https://enpicom.com/models-molecules/talip-ucar-inside-boltzs-open-source-bet-on-the-future-of-ai-driven-drug-discovery/ ]

Steve Comeau | From novel binder design to the realities of AI in complex therapeutics

Generative models can now propose novel antibody sequences from antigen structure alone, but how far does that actually get you? In this episode, we sit down with Principal Scientist Steve Comeau to discuss what current models can realistically deliver, where the data falls short, and why the harder problems are still ahead of us. Read the full conversation: ⁠⁠https://enpicom.com/models-molecules/steve-comeau-from-novel-binder-design-to-the-realities-of-ai-in-complex-therapeutics/ [https://enpicom.com/models-molecules/jiwon-kim-from-lab-in-the-loop-to-zero-shot-the-role-of-cloud-and-ai-agents/]

Jiwon Kim | From lab-in-the-loop to zero-shot: The role of cloud and AI agents

Jiwon Kim, Product Lead at AWS AI Life Sciences, joins Models & Molecules to break down pharma’s digital shift: where cloud and software are becoming core infrastructure for modern drug discovery. We touch upon the potential of agentic AI, why zero-shot models are the future, why lab in the loop is the essential bridge for getting there. Read the full conversation: ⁠https://enpicom.com/models-molecules/jiwon-kim-from-lab-in-the-loop-to-zero-shot-the-role-of-cloud-and-ai-agents/ [https://enpicom.com/models-molecules/jiwon-kim-from-lab-in-the-loop-to-zero-shot-the-role-of-cloud-and-ai-agents/]

Do Soon Kim | Navigating the convergence of tech and pharma

In this episode of Models & Molecules, Do Soon Kim, Head of Product at Xaira Therapeutics, discusses his journey in the biotech and AI sectors, emphasizing the importance of effective communication in fostering collaboration between different scientific disciplines. The conversation explores the potential of machine learning to reshape our understanding of intelligence and moving beyond the limits of human intuition to decode complex biology. Read the full interview: https://enpicom.com/models-molecules/do-soon-kim-navigating-the-convergence-of-tech-and-pharma/ [https://enpicom.com/models-molecules/do-soon-kim-navigating-the-convergence-of-tech-and-pharma/]

Jaap Goudsmit | From rabies to COVID: Antibody discovery in the age of AI

In this episode of Models & Molecules, Jaap Goudsmit, MD, PhD, immunologist, epidemiologist, and one of the scientific forces behind Crucell, the Dutch biotech acquired by Johnson & Johnson, explores the critical evolution of antibody research. Jaap reflects on the journey from traditional discovery to the complexities of modern drug development, highlighting the transformative role of AI and why high-quality training data is essential for the next generation of therapeutics. Read the full conversation: https://enpicom.com/models-molecules/jaap-goudsmit-from-rabies-to-covid-antibody-discovery-in-the-age-of-ai/